SG11201507305SA - Pharmaceutical combination drug - Google Patents
Pharmaceutical combination drugInfo
- Publication number
- SG11201507305SA SG11201507305SA SG11201507305SA SG11201507305SA SG11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical combination
- combination drug
- drug
- pharmaceutical
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130027114 | 2013-03-14 | ||
| PCT/KR2014/002178 WO2014142607A1 (fr) | 2013-03-14 | 2014-03-14 | Médicament combiné pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507305SA true SG11201507305SA (en) | 2015-10-29 |
Family
ID=51537139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507305SA SG11201507305SA (en) | 2013-03-14 | 2014-03-14 | Pharmaceutical combination drug |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9592233B2 (fr) |
| EP (1) | EP2974719B1 (fr) |
| JP (1) | JP6068765B2 (fr) |
| KR (1) | KR101502031B1 (fr) |
| CN (2) | CN110123771A (fr) |
| AU (1) | AU2014230182B2 (fr) |
| CA (1) | CA2905686C (fr) |
| ES (1) | ES2747098T3 (fr) |
| MX (1) | MX368148B (fr) |
| MY (1) | MY174729A (fr) |
| PH (1) | PH12015502108B1 (fr) |
| RU (1) | RU2639818C2 (fr) |
| SA (1) | SA515361123B1 (fr) |
| SG (1) | SG11201507305SA (fr) |
| WO (1) | WO2014142607A1 (fr) |
| ZA (1) | ZA201507576B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2017091041A1 (fr) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | Nouveau sel de fimasartan |
| CN105784867B (zh) * | 2016-03-28 | 2019-01-01 | 北京睿创康泰医药研究院有限公司 | 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途 |
| KR102201396B1 (ko) * | 2017-11-30 | 2021-01-11 | 보령제약 주식회사 | 피마살탄을 포함하는 약학적 조성물 |
| KR102078691B1 (ko) * | 2017-11-30 | 2020-02-19 | 보령제약 주식회사 | 피마살탄을 포함하는 고체 분산체 |
| KR101997652B1 (ko) * | 2018-01-22 | 2019-07-08 | 보령제약 주식회사 | 약학적 제제 |
| KR101992400B1 (ko) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | 약학적 제제 |
| KR102022694B1 (ko) * | 2019-02-20 | 2019-09-18 | 주식회사 네비팜 | 약학 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7396927B2 (en) * | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| CN101461799B (zh) * | 2008-12-31 | 2011-06-29 | 苏州中化药品工业有限公司 | 一种稳定的普伐他汀药物组合物及其制备方法 |
| ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| KR101058284B1 (ko) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법 |
| CN102666496B (zh) | 2010-01-21 | 2015-05-20 | 保宁制药株式会社 | 2-(2-正丁基-4-羟基-6-甲基-嘧啶-5-基)-n,n-二甲基乙酰胺的制备方法 |
| KR20110097168A (ko) | 2010-02-24 | 2011-08-31 | 근화제약주식회사 | 고지혈증 치료용 약제학적 복합제제 |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| CN101972260B (zh) * | 2010-11-24 | 2012-05-02 | 天津市汉康医药生物技术有限公司 | 一种瑞舒伐他汀钙口服药物组合物 |
| CN102485228B (zh) * | 2010-12-02 | 2015-06-10 | 鲁南制药集团股份有限公司 | 一种药物组合物及其用途 |
| UA110244C2 (en) * | 2011-04-12 | 2015-12-10 | Boryung Pharm | Antihypertensive pharmaceutical composition |
| KR101168136B1 (ko) * | 2011-08-08 | 2012-07-24 | 보령제약 주식회사 | 혈압 강하용 약제학적 조성물 |
-
2014
- 2014-03-14 CN CN201910375600.9A patent/CN110123771A/zh active Pending
- 2014-03-14 CN CN201480015539.2A patent/CN105120845A/zh active Pending
- 2014-03-14 ES ES14762250T patent/ES2747098T3/es active Active
- 2014-03-14 CA CA2905686A patent/CA2905686C/fr active Active
- 2014-03-14 AU AU2014230182A patent/AU2014230182B2/en not_active Ceased
- 2014-03-14 MY MYPI2015702913A patent/MY174729A/en unknown
- 2014-03-14 MX MX2015011988A patent/MX368148B/es active IP Right Grant
- 2014-03-14 JP JP2015562935A patent/JP6068765B2/ja not_active Expired - Fee Related
- 2014-03-14 WO PCT/KR2014/002178 patent/WO2014142607A1/fr active Application Filing
- 2014-03-14 KR KR1020140030190A patent/KR101502031B1/ko active IP Right Grant
- 2014-03-14 RU RU2015142255A patent/RU2639818C2/ru active
- 2014-03-14 SG SG11201507305SA patent/SG11201507305SA/en unknown
- 2014-03-14 EP EP14762250.0A patent/EP2974719B1/fr active Active
- 2014-03-14 US US14/774,927 patent/US9592233B2/en active Active
-
2015
- 2015-09-14 PH PH12015502108A patent/PH12015502108B1/en unknown
- 2015-09-14 SA SA515361123A patent/SA515361123B1/ar unknown
- 2015-10-12 ZA ZA2015/07576A patent/ZA201507576B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA515361123B1 (ar) | 2018-04-29 |
| EP2974719A4 (fr) | 2016-08-03 |
| ZA201507576B (en) | 2017-01-25 |
| CN105120845A (zh) | 2015-12-02 |
| WO2014142607A1 (fr) | 2014-09-18 |
| CA2905686C (fr) | 2017-06-27 |
| KR101502031B1 (ko) | 2015-03-12 |
| EP2974719B1 (fr) | 2019-08-28 |
| PH12015502108A1 (en) | 2016-01-18 |
| BR112015022000A2 (pt) | 2017-07-18 |
| MX2015011988A (es) | 2015-12-01 |
| JP2016512234A (ja) | 2016-04-25 |
| US9592233B2 (en) | 2017-03-14 |
| CN110123771A (zh) | 2019-08-16 |
| ES2747098T3 (es) | 2020-03-10 |
| PH12015502108B1 (en) | 2016-01-18 |
| MY174729A (en) | 2020-05-11 |
| KR20140113512A (ko) | 2014-09-24 |
| AU2014230182B2 (en) | 2016-12-22 |
| EP2974719A1 (fr) | 2016-01-20 |
| BR112015022000A8 (pt) | 2023-01-17 |
| AU2014230182A1 (en) | 2015-09-24 |
| RU2015142255A (ru) | 2017-04-26 |
| JP6068765B2 (ja) | 2017-01-25 |
| MX368148B (es) | 2019-09-20 |
| CA2905686A1 (fr) | 2014-09-18 |
| RU2639818C2 (ru) | 2017-12-22 |
| US20160022679A1 (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905426B (en) | Drug combinations | |
| HRP20180684T1 (hr) | Kombinacija lijekova | |
| GB201306610D0 (en) | Pharmaceutical compounds | |
| ZA201507576B (en) | Pharmaceutical combination drug | |
| HK1223833A1 (zh) | 藥物劑型 | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| ZA201506465B (en) | Pharmaceutical preparation | |
| GB201316662D0 (en) | Pharmaceutical Combination | |
| GB201310496D0 (en) | Pharmaceutical combinations | |
| GB201301723D0 (en) | Pharmaceutical combinations | |
| GB201308780D0 (en) | Pharmaceutical compounds |